Applications now open for AFE’s talent development programme
entertainment3 hours ago
The technical advisory group (TAG) of the WHO has sought additional clarifications from Bharat Biotech relating to its Covid-19 vaccine Covaxin.
The WHO said that TAG had asked Bharat Bitoech, the Hyderabad-based company, “to conduct a final emergency use listing (EUL) risk-benefit assessment for global use of Covaxin.
“The TAG expects to receive these clarifications from the manufacturer by the end of this week and aims to reconvene for the final risk-benefit assessment on November 3,” said the WHO. Last week, it had to thoroughly evaluate a vaccine to ensure it is safe; it could not ‘cut corners’ before recommending a vaccine for emergency use.
Covaxin is among the two widely-used anti-Covid vaccines in India. AstraZeneca’s Covishield, manufactured in India by Serum Institute, is the major one in the country. Serum Institute has supplied over a billion doses of Covishield in India and in other countries.
Bharat Biotech had claimed that it had done final analysis of the efficacy of the drug in phase 3 trials. Covaxin had shown 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent against the new Delta variant
Applications now open for AFE’s talent development programme
entertainment3 hours ago
Dubai Premier Padel P1 is part of a 25-tournament season that visits 18 countries across five continents
sports3 hours ago
His first job was in construction, which paid a salary of Rs150 — a significant sum at the time
uae3 hours ago
The emirate has proven itself to be one of the most attractive global destinations for investors
realty4 hours ago
Similar concept as Open-Book model trialled at schools here
education4 hours ago
Total assets increased by 7% from Dh6,240 million as of March 31 2023
realty4 hours ago
Spieth would become only the sixth player to complete the career Grand Slam if he wins this week
golf4 hours ago
In the first quarter, Dubai’s total transaction volumes reached 35,310
realty4 hours ago